In the PAH model, NF-κB signaling is activated, and sevoflurane can modulate NF-κB signaling by inhibiting p-IκB, p-p65, and p65 levels, reducing pulmonary fibrosis, and preventing PAH [40]. This evidence concerns the gene NFKB1 and pulmonary fibrosis.